

Supporting Table 4

Analysis of Overall survival (OS) Univariable Cox models (n=184).

| Variable | HR | 95%CI | p |
|--|-------|------------|-----------------|
| RCB score (by 1 point increase) | 1.96 | 1.49-2.59 | < 0.0001 |
| RCB class | / | / | / |
| ---0 | Ref. | Ref. | Ref. |
| ---1 | 3.39 | 0.62-18.50 | 0.159 |
| ---2 | 3.27 | 0.71-15.15 | 0.129 |
| ---3 | 12.89 | 2.91-57.16 | 0.001 |
| Age at entry (per 5 years increase) | 1.13 | 0.96-1.34 | 0.135 |
| Molecular breast cancer subtype | / | / | / |
| ---ER+/PR+ or -/ HER2- | Ref. | Ref. | Ref. |
| ---HER2+ (classical and variants) | 0.75 | 0.30-1.91 | 0.548 |
| ---Triple-negative | 1.27 | 0.53-3.01 | 0.592 |
| Tumor grade G3 | 2.01 | 0.81-4.95 | 0.131 |
| Ki-67 labeling index (per 10% increase) | 1.06 | 0.92-1.21 | 0.416 |
| Postmenopausal status | 1.59 | 0.73-3.45 | 0.239 |
| Neoadjuvant systemic therapy – Other regimens than sequential anthracycline + taxane (±anti-Her2)* | 3.10 | 1.25-7.67 | 0.014 |
| Breast conservation | 0.64 | 0.30-1.34 | 0.234 |
| Axillary lymph node dissection (ALND) | NE | NE | NE |
| Post-neoadjuvant tumor size (TNM ypT) | / | / | / |
| ---ypTis-ypT0 | Ref. | Ref. | Ref. |
| ---ypT1 | 1.77 | 0.56-5.56 | 0.328 |
| ---ypT2 | 5.02 | 1.51-16.68 | 0.002 |
| ---ypT3-ypT4 | 5.39 | 1.44-20.11 | 0.012 |
| Number of positive nodes (per 1 increase) | 1.13 | 1.08-1.19 | < 0.0001 |
| Post-neoadjuvant nodal status (TNM ypN) | / | / | / |
| ---ypN0 | Ref. | Ref. | Ref. |
| ---ypN1 | 1.91 | 0.69-5.30 | 0.216 |
| ---ypN2 | 3.35 | 1.10-10.20 | 0.033 |
| ---ypN3 | 7.56 | 2.71-21.13 | < 0.0001 |
| Adjuvant endocrine therapy | 0.57 | 0.27-1.22 | 0.148 |

Abbreviations: HR – hazard ratio, 95%CI – 95% confidence interval, Ref. – Reference category, ER – estrogen receptor, PR – progesterone receptor, | - or, HER-2 – human epidermal growth factor receptor 2 (erb-B2).